Loading
Inflammasome and Immune Disorders / Bone Metabolism and Diseases / Osteomyelitis and Bone Disorders Research · Journal article
Frontiers in Immunology · September 7, 2026
Raises a question worth testing. It does not answer one.
This narrative review synthesizes current understanding of NLRP3 inflammasome biology in osteomyelitis, identifying context-dependent roles in early antimicrobial defense versus chronic bone destruction, and proposes a stratified therapeutic framework combining NLRP3 modulation with antimicrobial and osteogenic strategies. The work is mechanistic and conceptual rather than evidence-generating, offering a theoretical foundation for future precision medicine approaches in osteomyelitis.
Journal article. Osteomyelitis patients and osteomyelitis models; review does not present primary data on any specific population..
NLRP3 inflammasome exhibits context-dependent roles: participates in antimicrobial defense during early infection but drives bone destruction and impaired repair in chronic phase Four mechanistic axes identified: IL-1β/RANKL/osteoclast axis driving infectious bone resorption; GSDMD/pyroptosis/DAMPs axis sustaining inflammatory loop; ROS/mitochondria/autophagy axis providing metabolic basis for persistent NLRP3 activation; osteoblast inhibition axis explaining repair failure Therapeutic candidates include NLRP3 small-molecule inhibitors, caspase-1 inhibitors, GSDMD/pyroptosis inhibitors, IL-1β/IL-1R blockade, and MSC-derived exosome therapy
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review frames NLRP3-targeted therapy as requiring stratified, stage-dependent intervention rather than uniform anti-inflammatory blockade, and advocates for combining inflammasome modulation with antimicrobial and osteogenic strategies through local delivery. Clinicians should note this represents a conceptual proposal requiring validation in controlled studies before clinical adoption.
This is a mechanistic review synthesizing existing knowledge about NLRP3 inflammasome roles in osteomyelitis pathogenesis and proposing therapeutic strategies, without reporting new experimental or clinical trial data.
This review frames NLRP3-targeted therapy as requiring stratified, stage-dependent intervention rather than uniform anti-inflammatory blockade, and advocates for combining inflammasome modulation with antimicrobial and osteogenic strategies through local delivery. Clinicians should note this represents a conceptual proposal requiring validation in controlled studies before clinical adoption.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Osteomyelitis is an inflammatory bone disease caused by pathogen infection, characterized by persistent infection, bone destruction, and impaired repair. Its refractoriness stems from the interplay between pathogen persistence and dysregulated host immune responses within the unique bone microenvironment. As a critical sensor of innate immunity, the NLRP3 inflammasome integrates pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), playing a pivotal regulatory role in the initiation and chronicity of osteomyelitis through caspase-1 activation, maturation and release of IL-1β and IL-18, and Gasdermin D (GSDMD)-mediated pyroptosis. This review systematically summarizes the activation mechanisms of the NLRP3 inflammasome within the bone immune microenvironment of osteomyelitis and its functions across multiple cell lineages. The local osteomyelitis microenvironment provides sustained NLRP3 activation signals through pathogen components, host damage signals, and bone matrix degradation products. Various cells, including macrophages, contribute to inflammatory amplification, enhanced bone resorption, or impaired repair via NLRP3-related pathways, forming a multi-layered pathological network through intercellular crosstalk. Mechanistically, four key axes operate: the IL-1β/receptor activator of nuclear factor-κB ligand (RANKL)/osteoclast axis driving infectious bone resorption; the GSDMD/pyroptosis/DAMPs axis sustaining a self-amplifying inflammatory loop; the reactive oxygen species (ROS)/mitochondria/autophagy axis providing the metabolic basis for persistent NLRP3 activation; and the osteoblast inhibition axis explaining post-infection repair failure. Notably, NLRP3 exhibits context-dependent roles in osteomyelitis—it may participate in antimicrobial defense during early infection, while in the chronic phase it primarily drives bone destruction and inadequate repair. Furthermore, Staphylococcus aureus can evade host defenses by attenuating NLRP3-mediated responses. Therapeutically, direct NLRP3 small-molecule inhibitors, caspase-1 inhibitors, GSDMD/pyroptosis inhibitors, IL-1β/IL-1R blockade, and mesenchymal stem cell (MSC)-derived exosome therapy all show potential value. However, the risk of systemic immunosuppression necessitates combining these strategies with adequate debridement and pathogen control. Local drug delivery systems, which achieve effective concentrations at the lesion while reducing systemic exposure, represent a more translationally promising direction. We propose that future NLRP3-targeted therapy for osteomyelitis should shift from “non-specific anti-inflammation” to “bone immune reprogramming”—stratified intervention based on infection stage, cell type, and inflammasome activation level, integrating NLRP3 modulation with antibacterial, anti-biofilm, anti-pyroptotic, and osteogenic-promoting strategies. This paradigm shift aims to transition from simple infection control to the reconstruction of a reparative bone immune microenvironment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.